A six-month combination trial
A randomized, double-blind trial studied 111 adults with nonalcoholic fatty liver disease, the terminology used in the publication. Participants received placebo or one of two amounts of a combined NR and pterostilbene product for six months. The primary endpoint, hepatic fat fraction, did not improve significantly relative to placebo. [1]
Some prespecified secondary measurements, including ALT and GGT liver enzymes, improved in the lower-amount group. A dose-dependent effect was not observed in the higher-amount group. The paper therefore reports a mixed pattern: a null primary result and favorable secondary laboratory findings in one treatment arm. [1]
Liver fat and liver enzymes are different endpoints
A summary that says “improved liver health” hides the distinction at the heart of this trial. Ask whether the claim concerns fat measured in the liver, a blood enzyme, a symptom or a longer-term disease outcome. Keep each result beside the method that produced it.
The negative primary endpoint should not be dismissed because another measure changed. Conversely, the favorable secondary findings need not be ignored. The useful task is to describe the pattern accurately and decide what a confirmatory study would need to test.
This is also a reason to avoid assuming that more of a supplement necessarily produces a larger clinical effect. A multi-arm design can investigate that question directly. A seller should not turn a higher labeled amount into a stronger efficacy claim without relevant evidence.
A blend cannot identify the contribution of each ingredient
The tested intervention contained both NR and pterostilbene. Without an appropriate component comparison, an observed effect of the blend cannot automatically be assigned to NR alone. It also cannot be assigned to every other blend that happens to contain NR.
When checking a product citation, compare the full formulation rather than only the first ingredient. Record whether the paper used the same combination, a single ingredient or a different route. Our ingredient guide helps separate related substances, while the NICE trial article illustrates a study that actually included a separate combination arm.
For someone managing a liver condition, these findings belong in a clinical discussion about the exact diagnosis and meaningful outcomes. They do not establish a replacement for ongoing care or a reason to interpret personal laboratory changes without context.
The most faithful consumer summary is brief: this particular combination did not significantly reduce the primary liver-fat measure in this trial. Some secondary markers improved and justify further investigation. Both halves should remain visible wherever the study is cited. Keep each treatment arm visible when comparing the reported enzyme changes.